Avinger, Inc. (AVGR)
USD 0.47
(-20.74%)
USD 0.47
(-20.74%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2 Million USD | -24.53% |
| 2022 | 2.65 Million USD | -22.49% |
| 2021 | 3.42 Million USD | 30.79% |
| 2020 | 2.61 Million USD | -8.69% |
| 2019 | 2.86 Million USD | 107.15% |
| 2018 | 1.38 Million USD | 145.11% |
| 2017 | -3.06 Million USD | -164.33% |
| 2016 | 4.76 Million USD | 12.61% |
| 2015 | 4.23 Million USD | -9.89% |
| 2014 | 4.7 Million USD | -1.24% |
| 2013 | 4.75 Million USD | 7.94% |
| 2012 | 4.4 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 378 Thousand USD | 10.2% |
| 2024 Q1 | 343 Thousand USD | -8.29% |
| 2023 Q4 | 374 Thousand USD | -3.61% |
| 2023 FY | 2 Million USD | -24.53% |
| 2023 Q2 | 605 Thousand USD | -4.87% |
| 2023 Q1 | 636 Thousand USD | -6.88% |
| 2023 Q3 | 388 Thousand USD | -35.87% |
| 2022 FY | 2.65 Million USD | -22.49% |
| 2022 Q4 | 683 Thousand USD | -13.54% |
| 2022 Q3 | 790 Thousand USD | 20.24% |
| 2022 Q2 | 657 Thousand USD | 25.38% |
| 2022 Q1 | 524 Thousand USD | -26.4% |
| 2021 FY | 3.42 Million USD | 30.79% |
| 2021 Q2 | 1.01 Million USD | 13.87% |
| 2021 Q3 | 800 Thousand USD | -21.41% |
| 2021 Q1 | 894 Thousand USD | -8.87% |
| 2021 Q4 | 712 Thousand USD | -11.0% |
| 2020 Q2 | 359 Thousand USD | -28.34% |
| 2020 Q3 | 777 Thousand USD | 116.43% |
| 2020 Q1 | 501 Thousand USD | -45.95% |
| 2020 Q4 | 981 Thousand USD | 26.25% |
| 2020 FY | 2.61 Million USD | -8.69% |
| 2019 Q2 | 720 Thousand USD | 93.03% |
| 2019 FY | 2.86 Million USD | 107.15% |
| 2019 Q4 | 927 Thousand USD | 9.45% |
| 2019 Q3 | 847 Thousand USD | 17.64% |
| 2019 Q1 | 373 Thousand USD | -33.15% |
| 2018 Q3 | 543 Thousand USD | 589.19% |
| 2018 FY | 1.38 Million USD | 145.11% |
| 2018 Q4 | 558 Thousand USD | 2.76% |
| 2018 Q2 | -111 Thousand USD | -128.17% |
| 2018 Q1 | 394 Thousand USD | 120.11% |
| 2017 Q2 | -1.46 Million USD | -150.0% |
| 2017 Q4 | 179 Thousand USD | 114.88% |
| 2017 Q1 | -584 Thousand USD | -159.53% |
| 2017 FY | -3.06 Million USD | -164.33% |
| 2017 Q3 | -1.2 Million USD | 17.6% |
| 2016 Q4 | 981 Thousand USD | -37.67% |
| 2016 FY | 4.76 Million USD | 12.61% |
| 2016 Q3 | 1.57 Million USD | 52.08% |
| 2016 Q2 | 1.03 Million USD | -12.21% |
| 2016 Q1 | 1.17 Million USD | 12.18% |
| 2015 FY | 4.23 Million USD | -9.89% |
| 2015 Q2 | 1.41 Million USD | 76.63% |
| 2015 Q1 | 800 Thousand USD | -46.74% |
| 2015 Q4 | 1.05 Million USD | 8.24% |
| 2015 Q3 | 971 Thousand USD | -31.28% |
| 2014 Q2 | 1.42 Million USD | 130.68% |
| 2014 Q3 | 1.16 Million USD | -18.3% |
| 2014 Q4 | 1.5 Million USD | 29.37% |
| 2014 Q1 | 616 Thousand USD | -41.39% |
| 2014 FY | 4.7 Million USD | -1.24% |
| 2013 Q3 | 1.56 Million USD | 45.73% |
| 2013 Q2 | 1.07 Million USD | 0.0% |
| 2013 FY | 4.75 Million USD | 7.94% |
| 2013 Q1 | 1.07 Million USD | 0.0% |
| 2013 Q4 | 1.05 Million USD | -32.76% |
| 2012 FY | 4.4 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 56.3 Million USD | 96.443% |
| AngioDynamics, Inc. | 154.69 Million USD | 98.705% |
| AtriCure, Inc. | 300.37 Million USD | 99.333% |
| Azenta, Inc. | 263.14 Million USD | 99.239% |
| BioLife Solutions, Inc. | 46.75 Million USD | 95.716% |
| The Cooper Companies, Inc. | 2.35 Billion USD | 99.915% |
| Daxor Corporation | 1.1 Million USD | -81.523% |
| Ekso Bionics Holdings, Inc. | 9.07 Million USD | 77.938% |
| Femasys Inc. | 691.9 Thousand USD | -189.492% |
| GlucoTrack, Inc. | -13 Thousand USD | 15507.692% |
| Harvard Bioscience, Inc. | 60.86 Million USD | 96.709% |
| Hologic, Inc. | 2.22 Billion USD | 99.91% |
| ICU Medical, Inc. | 739.87 Million USD | 99.729% |
| Intuitive Surgical, Inc. | 4.72 Billion USD | 99.958% |
| KORU Medical Systems, Inc. | 16.7 Million USD | 88.012% |
| LeMaitre Vascular, Inc. | 127.04 Million USD | 98.423% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 1778.553% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 1778.553% |
| Masimo Corporation | 1 Billion USD | 99.8% |
| Microbot Medical Inc. | -106 Thousand USD | 1989.623% |
| Meihua International Medical Technologies Co., Ltd. | 33.09 Million USD | 93.948% |
| Merit Medical Systems, Inc. | 583.87 Million USD | 99.657% |
| Nephros, Inc. | 8.4 Million USD | 76.169% |
| NovoCure Limited | 381.05 Million USD | 99.474% |
| NEXGEL, Inc. | 619 Thousand USD | -223.586% |
| NEXGEL, Inc. | 619 Thousand USD | -223.586% |
| Singular Genomics Systems, Inc. | -558 Thousand USD | 458.961% |
| OraSure Technologies, Inc. | 179.42 Million USD | 98.884% |
| Pro-Dex, Inc. | 14.55 Million USD | 86.235% |
| Pulse Biosciences, Inc. | -1.2 Million USD | 265.949% |
| Predictive Oncology Inc. | 1.14 Million USD | -74.889% |
| Precision Optics Corporation, Inc. | 5.79 Million USD | 65.452% |
| QuidelOrtho Corporation | 1.49 Billion USD | 99.866% |
| Repligen Corporation | 315.22 Million USD | 99.365% |
| Sanara MedTech Inc. | 57.13 Million USD | 96.494% |
| STAAR Surgical Company | 252.65 Million USD | 99.207% |
| Sharps Technology, Inc. | -891.24 Thousand USD | 324.741% |
| Utah Medical Products, Inc. | 30.03 Million USD | 93.332% |
| DENTSPLY SIRONA Inc. | 2.08 Billion USD | 99.904% |
| Jin Medical International Ltd. | 6.78 Million USD | 70.478% |